Centinel Spine® Quickly Achieves 1,000 Procedures with prodisc C Vivo and prodisc C SK Cervical Total Disc Replacement System as Rapid Market Adoption Continues

Centinel Spine®, LLC, (“the Company”) a leading global medical device company addressing cervical and lumbar spinal disease by providing the most robust and clinically-proven total disc replacement technology platform in the world (prodisc®), today announced the completion of the 1,000th procedure in the United States with the Company’s latest FDA-approved total disc replacement (TDR) system of prodisc® cervical solutions, prodisc C Vivo and prodisc C SK. The milestone comes two months after the Company completed 500 procedures with the system and validates the benefit of matching the implant to meet surgeon preference and patient needs. Since the limited launch of the new prodisc C Vivo and prodisc C SK system was initiated in September 2022, procedure volume with the new system has continued to grow exponentially—with an increase of over 60% in 1Q 2023 vs 4Q 2022.

According to spine surgeon Bradley Duhon, M.D., of Lone Tree, Colorado, “prodisc C Vivo comes with the trusted reputation of its Centinel Spine predecessors, but now with much easier implantation. It has become my ‘go-to’ disc replacement because it comes with very little bone work or prep. This not only makes for easier implantation, but also less endplate disruption, less bleeding, and less potential for heterotopic ossification.”

The prodisc C Vivo system has been in clinical use internationally since 2009 and is currently one of the most frequently implanted TDR devices in the world. The device has keel-less fixation and combines a unique anatomically-designed superior endplate with lateral spikes to optimize fit and provide immediate fixation.

The prodisc C SK device features a flat endplate design for optimized implant positioning that allows surgeons to address individual patient anatomy—and a low-profile central keel that provides immediate fixation and enables a streamlined keel preparation technique.

“The Match-the-Disc™ system of prodisc C Vivo and prodisc C SK, along with the original prodisc C, is exhibiting exponential growth,” observes Centinel Spine CEO Steve Murray. “With the addition of more instrument sets throughout the year, we will strive to support the unprecedented demand for this unique, paradigm-shifting total disc replacement system.”

The prodisc portfolio is the most extensive TDR system in the world, offering both cervical and lumbar implants with anatomically-differentiated designs. Centinel Spine is the only company with FDA approval for both cervical and lumbar TDR systems. All of the prodisc cervical and lumbar devices incorporate prodisc CORE technology, the basis behind the predictable clinical outcomes of the prodisc platform after 30 years and over 225,000 implantations worldwide.*

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.